Back to headlines
HealthcareDecember 30, 2025

Cyberknight Therapeutics Secures FDA Nod for Myqorzo Heart Drug, Phase 3 Success

  • FDA Greenlights Myqorzo! Cytokinetics bags its first-ever U.S. approval for the heart drug after 28 years of hustle.
  • Phase 3 Knockout Punch: SEQUOIA-HCM trial crushes it, proving Myqorzo boosts functional capacity and tames symptoms in obstructive HCM patients.
  • Blockbuster Battle Royale: Myqorzo dives into the ring against Bristol Myers' Camzyos, with U.S. launch eyed for late January 2026.

Hold onto your stethoscopes, cardio cowboys—Cytokinetics just drop-kicked despair into the dustbin with a FDA fastball: MYQORZO™ (aficamten), the rebel heart drug that's got obstructive hypertrophic cardiomyopathy (oHCM) quaking in its ventricles! On December 19, 2025, the FDA slapped its golden stamp on this cardiac myosin inhibitor, greenlighting it for adults with symptomatic oHCM to supercharge functional capacity and kick symptoms to the curb. After 28 gritty years grinding in the biotech Badlands, Cytokinetics finally claims its first U.S. trophy. Talk about a heartbeat comeback!

Picture this: oHCM, the sneaky beast where hypercontractile heart muscles turn your pump into a traffic jam, blocking outflow and leaving patients gasping. Enter Myqorzo, the allosteric assassin that dials down myosin madness, easing left ventricular outflow tract (LVOT) obstruction like a chill pill for your ticker. The Phase 3 SEQUOIA-HCM trial? Pure fireworks. Patients on Myqorzo strutted farther on treadmill tests, ditched breathlessness, and lived larger—statistically savage results that had regulators nodding faster than a DJ at a rave.

But wait, the plot thickens! This isn't some lone ranger rodeo. Myqorzo's already moseyed into China with NMPA approval on December 17, pocketing Cytokinetics a cool $7.5 million milestone from partner Sanofi (with royalties chasing). Europe's CHMP just tossed a positive opinion on December 12, eyeing full EU blessing by Q1 2026. And the real spice? Myqorzo's saddling up against Bristol Myers Squibb's Camzyos, the $1B sales stallion. Cytokinetics' CEO Fady Ibraham crowed, "We're accelerating commercial readiness—patients, your knight in shining armor has arrived!"

Wall Street went wild: CYTK shares galloped post-announcement, turning skeptics into superfans. "From zero to hero," quipped analysts, as the Bay Area biotech (not some phantom Cyberknight—get your wires straight!) proves perseverance pays. U.S. launch? Late January 2026, tablets in 5mg to 20mg doses. Doctors are drooling; patients are pumped.

In a year of heart failure headlines, Myqorzo steals the show—proving science doesn't just heal, it heroes up. Will it dethrone Camzyos? Grab popcorn; this cardiac cage match is just warming up. Hearts worldwide, rejoice: the beat goes on, stronger than ever!